title: Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
abstract: Lansoprazole (LPZ), amoxicillin (AMPC) and clarithromycin (CAM) are commonly used drugs (LAC regimen) for Helicobacter pylori (H. pylori) eradication, but the eradication rate with this regimen was reported to be 70% to 90%. A few studies have reported that a successful eradication was associated with the CYP2C19 genotype, which influences the metabolism of proton pump inhibitors (PPI) including LPZ. This study examined the changes in the H. pylori eradication rates between the periods before and after the commencement of a routine genetic test for CYP2C19 at the Daiko Medical Center in Nagoya, Japan, in November, 2005. Subjects were patients who visited the Center during the period from June, 2004 to August, 2010. The patients were classified into three groups according to their CYP2C19 genotype: rapid metabolizers (RM) with a *1*1 genotype, intermediate metabolizers (IM) with a *1*2 or *1*3 genotype, and poor metabolizers (PM) with a *2*2, *2*3, or *3*3 genotype. Non-rapid metabolizers (IM and PM) were basically treated with a LAC regimen, while RMs were treated with a RAM reg imen(rabeprazole, AMPC, and metronidazole). The eradication rate was 80.0% (n=90) for the period without the genetic testing and 88.7% (n=124) for the period with the genetic testing (chi2=3.11, p=0.078). The age-sex adjusted odds ratio of eradication success was 2.29 (95% confidence interval, 0.99-5.28, p=0.051) for the latter period relative to the former period among those less than 70 years of age. Those results suggested that the routine genetic test which allows a choice of the RAM regimen for R M improved the eradication rate.
authors: Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Japan. tamura.takashi@c.mbox.nagoya-u.ac.jp
authors: Takashi
authors: T
authors: Tamura
authors: Mio
authors: M
authors: Kurata
authors: Shigeru
authors: S
authors: Inoue
authors: Takaaki
authors: T
authors: Kondo
authors: Yasuyuki
authors: Y
authors: Goto
authors: Yoshikazu
authors: Y
authors: Kamiya
authors: Sayo
authors: S
authors: Kawai
authors: Nobuyuki
authors: N
authors: Hamajima
references: Jpn J Cancer Res. 2000 Sep;91(9):865-8
references: 11011111
references: Aliment Pharmacol Ther. 2003 Mar 15;17(6):751-64
references: 12641497
references: Helicobacter. 2008 Dec;13(6):532-41
references: 19166419
references: Clin Microbiol Infect. 2005 Apr;11(4):307-11
references: 15760428
references: Clin Pharmacol Ther. 2007 Apr;81(4):521-8
references: 17215846
references: Aliment Pharmacol Ther. 1999 Jun;13(6):741-6
references: 10383502
references: J Gastroenterol Hepatol. 2002 Jul;17(7):748-53
references: 12121503
references: Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73
references: 15952098
references: Helicobacter. 2001 Sep;6(3):254-61
references: 11683930
references: J Gastroenterol. 2000;35(1):10-4
references: 10632534
references: Int J Med Sci. 2006 Sep 10;3(4):135-40
references: 17003844
references: J Clin Microbiol. 2007 Dec;45(12):4006-10
references: 17942652
references: Hepatogastroenterology. 2007 Mar;54(74):649-54
references: 17523342